Kadmon Nabs Dyax’ MMP-14 Inhibitor mAb
Kadmon negotiated an exclusive worldwide license to develop Dyax’s fully human monoclonal antibody matrix metalloproteinase 14 (MMP14) inhibitor DX-2400, which is currently undergoing IND-enabling studies.
Espero, Armetheon Plan Merger into Commercial-Stage Cardiovascular BioPharma
New biopharma will start out with marketed angina drug, pivotal-stage anticoagulant and Phase II-stage antiarrhythmic
GSK, Zymeworks Launch Up-to-$440M+ Antibody Collaboration
Companies to design and commercialize new Fc-engineered monoclonal and bi-specific antibody drugs using Zymeworks' EEFECT platform
TaiGen Acquires Global Rights to Warner Chilcott’s Late-Stage Antibiotic
Taiwanese firm projects completing Phase III trials with oral nemonoxacin in China and Taiwan during 2012.
Cancer Immunotherapy May Improve with Identification of New Mutations
Future T cell therapies with less side effects.
Roivant’s Newest Company to Develop Ligand’s Diabetes Candidate LGD-6972
Ligand Pharmaceuticals could generate up to $533.8 million+ through partnership with Roivant, which will develop the Phase III-ready glucagon receptor antagonist LGD-6972
FDA Rejects NDAs for Cempra Bacterial Pneumonia Candidate Solithromycin
Agency says additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies needed before the NDAs can be approved
Antibiotic-Antigen Conjugates Bring Immunotherapy to Deadly Bacteria
Immunobiotics, small molecules that combine immunostimulatory agents and antbiotics, decrease the number of live gram-negative bacteria in human serum.
Nanosponge Vaccine Breaks through Safety/Efficacy Tradeoff
A nanoparticle-based toxin-detainment strategy is used to safely deliver non-disrupted pore-forming toxins for immune processing.
Celgene Launches $1B Immunotherapy Collaboration with Juno
Companies will develop cancer and autoimmune disease treatments based on CAR-T and T cell receptor technologies over a 10-year period
